Get the Stockscreener App
200.91
1.12%
-2.28
Pre-market:
201.79
0.88
+0.44%
Natera Inc stock is traded at $200.91, with a volume of 1.47M.
It is down -1.12% in the last 24 hours and down -1.39% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$203.19
Open:
$205.47
24h Volume:
1.47M
Relative Volume:
1.05
Market Cap:
$28.77B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-122.42
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+2.48%
1M Performance:
-1.39%
6M Performance:
-15.27%
1Y Performance:
+31.04%
1-Day Range:
$197.63
$209.00
1-Week Range:
$197.16
$210.67
52-Week Range:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
200.91 | 29.10B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
448.18 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.81 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.21 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.64 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.08 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera Clinical Milestones Raise Questions On Growth Versus Valuation Risk - simplywall.st
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Natera Expands Austin Operations With New Sequencing Facility - Yahoo Finance
Natera enhances prenatal test, cuts no-call rate to 0.5% - Investing.com
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology - Yahoo Finance
(NTRA) Risk Channels and Responsive Allocation - Stock Traders Daily
Natera, Inc. (NTRA) Stock Analysis: Riding High On A 28.4% Potential Upside - DirectorsTalk Interviews
What's Driving Natera's Recent Stock Action - Kavout
How The Natera (NTRA) Investment Story Is Shifting With New Guidance And Analyst Revisions - Yahoo Finance
Is It Time To Reconsider Natera (NTRA) After Its Strong Five Year Share Price Gain - simplywall.st
NTRA Stock Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology - BioSpace
Natera to present 35 oncology abstracts at ASCO meeting By Investing.com - Investing.com South Africa
Natera to present 35 oncology abstracts at ASCO meeting - Investing.com UK
Mid-Cap Stocks Analysis: Natera to Buy, Graco and Jacobs Solutions to Sell | StockStoryNews and Statistics - IndexBox
35 Natera studies test ctDNA to flag cancer return at ASCO - Stock Titan
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $220 to $285 - Moomoo
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone - The Globe and Mail
Natera announces expansion into Austin, creating largest sequencing factory - TipRanks
Natera Expands Operations in Austin - Moomoo
Natera expands Austin facility, plans to add 400 jobs - Investing.com
Natera expands Austin facility, plans to add 400 jobs By Investing.com - Investing.com Canada
Natera, Inc. Expands Operations in Austin with New Sequencing Facility and Additional Lab Space - marketscreener.com
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling? - Kavout
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Expands Clinical Trial Enrollment to Over 2,000 Pa - GuruFocus
Natera Expands Enrollment in Fetal Genetic Testing Study - Moomoo
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Natera’s EXPAND trial enrolls over 2,000 patients - Investing.com UK
Natera’s EXPAND trial enrolls over 2,000 patients By Investing.com - Investing.com Australia
Study of prenatal gene risk test now passes 2,000 patients - Stock Titan
Quinn Emanuel Owes More Sanctions In Guardant Fight - Law360
FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA) - simplywall.st
Is It Time To Reassess Natera (NTRA) After The Recent Share Price Pullback - Yahoo Finance
Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer - Quiver Quantitative
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer - The Globe and Mail
Natera wins FDA approval for companion diagnostic - MedTech Dive
What's Behind Natera CEO Steven Chapman's Recent Stock Sales - Kavout
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - Yahoo Finance
A Look At Natera (NTRA) Valuation After Recent Share Price Weakness - simplywall.st
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Natera, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman - GuruFocus
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock By Investing.com - Investing.com Nigeria
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com India
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.51%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):